These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 1931705

  • 1. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
    Boussiotis VA, Pangalis GA.
    Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
    [Abstract] [Full Text] [Related]

  • 2. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia.
    McSweeney EN, Giles FJ, Worman CP, Jewel AP, Tsakona CP, Hoffbrand AV, Mehta AB, Newland AC, Cawley JC, Galvani D.
    Br J Haematol; 1993 Sep; 85(1):77-83. PubMed ID: 8251412
    [Abstract] [Full Text] [Related]

  • 3. Randomized clinical trial with alpha 2b-interferon in 26 stage A untreated B-chronic lymphocytic leukemia patients.
    Boussiotis VA, Pangalis GA.
    Nouv Rev Fr Hematol (1978); 1988 Sep; 30(5-6):471-3. PubMed ID: 3065744
    [Abstract] [Full Text] [Related]

  • 4. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report.
    Pangalis GA, Griva E.
    Cancer; 1988 Mar 01; 61(5):869-72. PubMed ID: 3338053
    [Abstract] [Full Text] [Related]

  • 5. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA.
    Leuk Lymphoma; 2003 Jan 01; 44(1):39-48. PubMed ID: 12691141
    [Abstract] [Full Text] [Related]

  • 6. Interferon-alpha 2b (IFN alpha) for early-phase chronic lymphocytic leukaemia with high risk for disease progression: results of a randomized multicentre study.
    Langenmayer I, Nerl C, Knauf W, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HW, Thiel E, Emmerich B.
    Br J Haematol; 1996 Aug 01; 94(2):362-9. PubMed ID: 8759897
    [Abstract] [Full Text] [Related]

  • 7. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC.
    J Hepatol; 1995 Nov 01; 23(5):487-96. PubMed ID: 8583134
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
    Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JY, Maertens G, Gogate J, Sanghvi B, Albrecht J.
    Hepatology; 1996 Nov 01; 24(5):1034-40. PubMed ID: 8903371
    [Abstract] [Full Text] [Related]

  • 11. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.
    Lancet; 2001 Sep 22; 358(9286):958-65. PubMed ID: 11583749
    [Abstract] [Full Text] [Related]

  • 12. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2.
    Ziegler-Heitbrock HW, Schlag R, Flieger D, Thiel E.
    Blood; 1989 May 01; 73(6):1426-30. PubMed ID: 2713486
    [Abstract] [Full Text] [Related]

  • 13. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H, Nordic Melanoma Cooperative Group.
    Lancet Oncol; 2011 Feb 01; 12(2):144-52. PubMed ID: 21256809
    [Abstract] [Full Text] [Related]

  • 14. Evolving modalities of treatment with interferon alfa-2b for Ph1-positive chronic myelogenous leukaemia.
    Morra E, Alimena G, Lazzarino M, Liberati AM, Montefusco E, Bernasconi P, Mancini M, Donti E, Merante S, Dianzani F.
    Eur J Cancer; 1991 Feb 01; 27 Suppl 4():S14-7. PubMed ID: 1799466
    [Abstract] [Full Text] [Related]

  • 15. Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-alpha 2B therapy.
    Demeter J, Paloczi K, Bibok G, Lehoczky D.
    Leukemia; 1992 Feb 01; 6 Suppl 3():41S-45S. PubMed ID: 1602826
    [Abstract] [Full Text] [Related]

  • 16. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP.
    Hepatology; 1998 Dec 01; 28(6):1680-6. PubMed ID: 9828235
    [Abstract] [Full Text] [Related]

  • 17. Recombinant interferon-alpha 2A as maintenance treatment for patients with advanced stage chronic lymphocytic leukemia responding to chemotherapy.
    Ferrara F, Rametta V, Mele G, Antinolfi I, Mettivier V, Cimino R.
    Am J Hematol; 1992 Sep 01; 41(1):45-9. PubMed ID: 1503098
    [Abstract] [Full Text] [Related]

  • 18. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G.
    New Microbiol; 2005 Jan 01; 28(1):23-9. PubMed ID: 15782623
    [Abstract] [Full Text] [Related]

  • 19. alpha Interferon in chronic lymphocytic leukaemia.
    Montserrat E, Villamor N, Urbano-Ispizua A, Ribera JM, Rozman C.
    Eur J Cancer; 1991 Jan 01; 27 Suppl 4():S74-7. PubMed ID: 1839211
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.